Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00976248 · OUTCOME

Time to Next Therapy With Single Agent RAD001 Therapy in Previously Untreated WM

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia · Source last updated 2018-10-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
Full Range
Time frame
End of follow-up, an average of 18 months

Analysis population: 13 participants were censored due to follow-up ending prior to new therapy initiation.

Groups in this outcome

RAD001

RAD001, oral, 10 mg, daily RAD001: Taken orally once a day

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
RAD00120

Reported measurements

Source class 1
Values in Months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
RAD00115Not reported169Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        69
        value
        15
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
dispersion Type
Full Range
groups
  1. description
    RAD001, oral, 10 mg, daily RAD001: Taken orally once a day
    id
    OG000
    title
    RAD001
param Type
MEDIAN
population Description
13 participants were censored due to follow-up ending prior to new therapy initiation.
reporting Status
POSTED
time Frame
End of follow-up, an average of 18 months
title
Time to Next Therapy With Single Agent RAD001 Therapy in Previously Untreated WM
type
PRIMARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice